| Roberta Van Amber Prigge, | |
|
9555 Upland Ln N, Maple Grove, MN 55369-4485 | |
| (952) 831-8742 | |
| Not Available |
| Full Name | Roberta Van Amber Prigge |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 29 Years |
| Location | 9555 Upland Ln N, Maple Grove, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639102825 | NPI | - | NPPES |
| 795820000 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QS0010X | Family Medicine - Sports Medicine | 39190 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Park Nicollet Clinic | 7911819438 | 1529 |
News Archive
Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report that it will be featured on two broadcast radio shows beginning tomorrow with Stu Taylor and the "Equity Strategies Show". Mr. Taylor will interview Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., discussing the Company's strategies with its FDA Drug approval programs, the Company's progress to date with its critical drug release programs, and future planning for subsequent drug releases through additional Federal and State government agencies.
Being under stress diminishes our abilities to predict new dangers that we face, a team of psychology researchers finds. Its work runs counter to the conventional view that stress enhances our ability to detect and adjust to these changing sources of threat.
NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.
Patients with leg pain caused by arterial disease may be able to forego treatment of the affected artery by participating in hospital-supervised exercise, according to a new study published in the February issue of Radiology.
› Verified 2 days ago
| Entity Name | Park Nicollet Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780621904 PECOS PAC ID: 7911819438 Enrollment ID: O20031104000046 |
News Archive
Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report that it will be featured on two broadcast radio shows beginning tomorrow with Stu Taylor and the "Equity Strategies Show". Mr. Taylor will interview Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., discussing the Company's strategies with its FDA Drug approval programs, the Company's progress to date with its critical drug release programs, and future planning for subsequent drug releases through additional Federal and State government agencies.
Being under stress diminishes our abilities to predict new dangers that we face, a team of psychology researchers finds. Its work runs counter to the conventional view that stress enhances our ability to detect and adjust to these changing sources of threat.
NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.
Patients with leg pain caused by arterial disease may be able to forego treatment of the affected artery by participating in hospital-supervised exercise, according to a new study published in the February issue of Radiology.
› Verified 2 days ago
| Entity Name | Tria Orthopaedic Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518273085 PECOS PAC ID: 3173570561 Enrollment ID: O20110310000999 |
News Archive
Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report that it will be featured on two broadcast radio shows beginning tomorrow with Stu Taylor and the "Equity Strategies Show". Mr. Taylor will interview Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., discussing the Company's strategies with its FDA Drug approval programs, the Company's progress to date with its critical drug release programs, and future planning for subsequent drug releases through additional Federal and State government agencies.
Being under stress diminishes our abilities to predict new dangers that we face, a team of psychology researchers finds. Its work runs counter to the conventional view that stress enhances our ability to detect and adjust to these changing sources of threat.
NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.
Patients with leg pain caused by arterial disease may be able to forego treatment of the affected artery by participating in hospital-supervised exercise, according to a new study published in the February issue of Radiology.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Roberta Van Amber Prigge, 8170 33rd Ave S # Ms 21110q, Bloomington, MN 55425-4516 Ph: () - | Roberta Van Amber Prigge, 9555 Upland Ln N, Maple Grove, MN 55369-4485 Ph: (952) 831-8742 |
News Archive
Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report that it will be featured on two broadcast radio shows beginning tomorrow with Stu Taylor and the "Equity Strategies Show". Mr. Taylor will interview Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., discussing the Company's strategies with its FDA Drug approval programs, the Company's progress to date with its critical drug release programs, and future planning for subsequent drug releases through additional Federal and State government agencies.
Being under stress diminishes our abilities to predict new dangers that we face, a team of psychology researchers finds. Its work runs counter to the conventional view that stress enhances our ability to detect and adjust to these changing sources of threat.
NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.
Patients with leg pain caused by arterial disease may be able to forego treatment of the affected artery by participating in hospital-supervised exercise, according to a new study published in the February issue of Radiology.
› Verified 2 days ago
Dr. Pamela D Doorenbos, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 9825 Hospital Dr, Suite 300, Maple Grove, MN 55369 Phone: 763-494-7500 Fax: 763-494-7501 | |
Keith Johnson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9855 Hospital Dr Ste 102, Maple Grove, MN 55369 Phone: 763-581-5900 Fax: 763-581-5901 | |
Dr. Mark S Hench, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 9855 Hospital Dr, Ste 102a, Maple Grove, MN 55369 Phone: 763-581-9220 | |
Mirtha Nesheim, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12000 Elm Creek Blvd N, Maple Grove, MN 55369 Phone: 763-420-5822 Fax: 763-420-6387 | |
Ronald B Boeding, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9645 Grove Cir N Ste 200, Maple Grove, MN 55369 Phone: 763-201-8191 Fax: 763-201-8192 | |
Moushumi Meher, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9825 Hospital Dr Ste 300, Maple Grove, MN 55369 Phone: 763-587-7900 Fax: 763-494-7501 | |
Pamela Kolacz, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6320 Wedgwood Rd N, Maple Grove, MN 55311 Phone: 763-268-0400 Fax: 763-268-0405 |